Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Pediatr Res. 2015 Aug 31;78(6):634–640. doi: 10.1038/pr.2015.166

Figure 2.

Figure 2

Loss of EC-SOD causes pulmonary hypertension at baseline in neonatal mice, which is worsened by treatment with bleomycin. Figure 2a. RV/LV +S weight at 4 weeks in WT and EC-SOD KO mice following IP PBS or bleomycin treatment, *p < 0.05 for strain by 2 -way ANOVA. Figure 2b. RVSP by direct RV puncture at 4 weeks of age in WT and EC-SOD KO mice following IP PBS or bleomycin treatment, * p < 0.01 for strain by 2-way ANOVA. Figure 2c. LV/body weight at 4 weeks of age in WT and EC-SOD KO mice following IP PBS or bleomycin, * p < 0.05 for treatment by 2-way ANOVA. Figure 2d. RV/LV+S weight at 3 weeks in WT and EC-SOD KO mice following IP PBS or bleomycin treatment, * p = 0.06 for strain, ** p < 0.005 for treatment by 2-way ANOVA, n=3–8.